Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2 Days untill FDA Decision ....
$9+ before FDA Decision on Thursday is possible then jump to $11-13 on approval
Deals which just closed in last 6 months :
Bausch Health acquires U.S. rights for Eton's eye drop ..2019-02-19
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aBHC-2719331
"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019.
EM-100 Ophthalmic Solution
•Innovative over-the-counter ophthalmic solution for treatment of allergic conjunctivitis
•If approved, EM-100 would be the first preservative-free ophthalmic product indicated for allergic conjunctivitis
•Product has been filed with the FDA and is expected to be approved in 2019
•U.S. allergic conjunctivitis ophthalmic market is >$600 million annually
•Eton partnered with Bausch Health for commercialization
•Eton receives additional milestone payment upon approval and a royalty on net sales
Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-licensing-lamotrigine-new-drug
Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients
NDA was submitted in May 2019; product launch anticipated in 1H 2020
Lamotrigine market currently exceeds $700 million annually
Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-enters-license-agreement-two-branded
Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-licensing-oral-liquid-product
First FDA Decision this Thursday ............
"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019. Bausch Health will be responsible for all remaining regulatory and commercial activities surrounding the product. Eton is entitled to a milestone payment upon product launch and a royalty on commercial sales."
Eton Pharmaceuticals (NASDAQ:ETON) Given New $18.00 Price Target at HC Wainwright
“We have valued Eton based on a discounted cash flow (DCF) assessment, driven by our projection of future sales and royalty-based revenue from three candidates in the company’s pipeline, namely EM-100, ET-202 and CT-100. Our valuation approach utilizes a 12% discount rate and 2% terminal growth rate, along with a 28% effective tax rate applied to future cash flows. We assign a 90% probability of regulatory approval to EM-100, an 85% probability of approval to ET-202, which have already been filed with the 80% probability of approval to ET-103.”,” the firm’s analyst commented.
(ETON) First FDA Decision in 10 Days if approved stock likely to jump above $11+ especially because of its very low float .Market Cap only $139 million at $7.90 share price .GL
EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019.
EM-100 Ophthalmic Solution
•Innovative over-the-counter ophthalmic solution for treatment of allergic conjunctivitis
•If approved, EM-100 would be the first preservative-free ophthalmic product indicated for allergic conjunctivitis
•Product has been filed with the FDA and is expected to be approved in 2019
•U.S. allergic conjunctivitis ophthalmic market is >$600 million annually
•Eton partnered with Bausch Health for commercialization
•Eton receives additional milestone payment upon approval and a royalty on net sales
(ETON) First FDA Decision in 10 Days if approved stock likely to jump above $11+ especially because of its very low float .Market Cap only $139 million at $7.90 share price .GL
EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019.
EM-100 Ophthalmic Solution
•Innovative over-the-counter ophthalmic solution for treatment of allergic conjunctivitis
•If approved, EM-100 would be the first preservative-free ophthalmic product indicated for allergic conjunctivitis
•Product has been filed with the FDA and is expected to be approved in 2019
•U.S. allergic conjunctivitis ophthalmic market is >$600 million annually
•Eton partnered with Bausch Health for commercialization
•Eton receives additional milestone payment upon approval and a royalty on net sales
(ETON)..Market Cap $133 M / 2 FDA decisions imminent for attractive products on July 11 and next one on October 21 / HUGE late stage pipeline with multiple milestones in near-term milestones /undiscovered Ultra low float stock = Potential 1000% GEM
Eton Pharma (ETON)
Market-cap: $130,7 Million
Cash: $19,5 Million
Price: $7,42
Shares Out: 17,6 Million
Presentation May 2019
insert-text-here
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
Largest Shareholders
Harrow Health, Inc...3,500,000
Peter A. Appel...1,249,329 ´
Sean Brynjelsen, MBA...1,034,940
Mark L. Baum...794,745
Charles J. Casamento, MBA...60,420
Paul V. Maier, MBA...59,745
Norbert G. Riedel, PhD ...59,745
Wilson W. Troutman, CPA...5,000
https://thefly.com/landingPageNews.php?id=2925035&headline=ETON-Eton-Pharmaceuticals-analyst-commentary-
Eton Pharmaceuticals price target raised to $18 from $15 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Eton Pharmaceuticals to $18 from $15 after the company in-licensed ET-105, a patent-pending formulation of lamotrigine designed to be delivered to patients as an oral liquid, from the privately-held Aucta Pharmaceuticals. The analyst believes the in-licensing of ET-105 meaningfully expands Eton's "stable" of neurology-focused product candidates. He reiterates a Buy rating on the shares.
(ETON)..Market Cap $133 M / 2 FDA decisions imminent for attractive products on July 11 and next one on October 21 / HUGE late stage pipeline with multiple milestones in near-term milestones /undiscovered Ultra low float stock = Potential 1000% GEM
Eton Pharma (ETON)
Market-cap: $130,7 Million
Cash: $19,5 Million
Price: $7,42
Shares Out: 17,6 Million
Presentation May 2019
insert-text-here
•Diversified pipeline of 11 products under development. Four products submitted to the FDA,three additional NDA’s expected to be submitted in 2019
•Expect to become commercial revenue company in 2019
Largest Shareholders
Harrow Health, Inc...3,500,000
Peter A. Appel...1,249,329 ´
Sean Brynjelsen, MBA...1,034,940
Mark L. Baum...794,745
Charles J. Casamento, MBA...60,420
Paul V. Maier, MBA...59,745
Norbert G. Riedel, PhD ...59,745
Wilson W. Troutman, CPA...5,000
https://thefly.com/landingPageNews.php?id=2925035&headline=ETON-Eton-Pharmaceuticals-analyst-commentary-
Eton Pharmaceuticals price target raised to $18 from $15 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Eton Pharmaceuticals to $18 from $15 after the company in-licensed ET-105, a patent-pending formulation of lamotrigine designed to be delivered to patients as an oral liquid, from the privately-held Aucta Pharmaceuticals. The analyst believes the in-licensing of ET-105 meaningfully expands Eton's "stable" of neurology-focused product candidates. He reiterates a Buy rating on the shares.
FDA approval expected in Q3
major news imminent
strong buy
i like it
(NAOV) MC $27 Million /Shares Out 6.4 M / Float 1 M / 2 Products approved in US / 1 Potential Blockbuster expected to be approved in Q3 = 1000%+ UPSIDE on this unknown GEM...
NanoVibronix (NAOV)
Market Cap $27 Million
Shares Out 6.4Million
Price $4.10
i24 News Reports on the Effects of the PainShield (APPROVED IN US)
insert-text-here
UroShield: for the prevention of bacterial colonization and biofilm in urinary catheters.Currently CE Marked, an FDA De Novofiling for UroShield is anticipated in 1H 2019. If all goes to plan, the device could make its U.S. introduction later this year. The target market is big(24M indwelling catheters sold in the U.S. each year) and largely underserved (antibiotics are first-line treatment yet often prove to be ineffective)1. Indwelling catheter induced urinary tract infections are commonplaceand, given that they cost the healthcare system billions of dollars each year, hospitals have an economic interest to adopt novel technologies (potentially such as UroShield) that can prevent them.
PainShield: for the treatment of pain, muscle spasms and tendon diseases. The product has U.S. 510(k) clearance, CE Marking and Health Canada regulatory approval.At-home use for trigeminal neuralgia (TN), a neurological condition characterized by extreme pain along the trigeminal nerve in the face, is the main focused market for PainShield. First-line treatment oftrigeminal neuralgia, which causes such severe pain thatit has been called the suicide disease, are anticonvulsants. Surgery and opioids may also be used. While medications can be initially effective, their ability to control the disease usually wanes over time. Estimated U.S. incidence of TN isbetween ~40k and 140k. General soft tissue pain represents a less-defined but relatively enormous market and potent opportunity for PainShield, as does the recent crackdown on opioid overprescribing.
WoundShield: to speed the healing of hard-to-treat wounds.
WoundShield is CE Marked and has Health Canada approval. The chronic wound market is large and encompassesdiabetic foot ulcers (U.S. prevalence is ~5.5M with recurrence rate of 66%), venous leg ulcers (U.S. prevalence is ~600k with one-third recurring four or more times) and pressure ulcers (U.S. incidence of ~2.5M). An estimated $25B or more is spent each year on treating chronic wounds. While there are several modalities of advanced wound therapies available with varying degrees of effectiveness, almost all require operation by a trained clinician and a trip to the hospital. By contrast, WoundShield is designed for at-home use by an individual patient. Another potentially potent, and largely unique, advantage of WoundShield is the ability to use it as an adjunct, or complement, to existing advanced wound care modalities
LungShield: similar in form to UroShield but different in its application, LungShield is designed to reduce the risk of endotracheal infection in a hospital setting. It is currently being evaluated in a human pilot study in patients undergoing mechanical ventilation to determine its effect on development of bacterial colonies on endotracheal tubes
RenooSkin: to facilitate rejuvenationof facial skin.Unlike the NAOVs other products in which the transducer is enclosed in a patch or clip, RenooSkin consists of a head band-like applicator which houses two transducers near each ear. In vitro studies have indicated RenooSkin may be as effective as Retin-A (tretinoin, which generates ~$300M in annual sales)in its ability to rejuvenate skin. Target market is the non-prescription skincare space. Skin care is a very large market, generating ~$8B in annual sales in the U.S. Facial skin care is the fastest growing subcategory within skin care with sales of products such as facemasks, facial moisturizers and facial sprays increasing by as much as 39% annually
We recently met with the FDA and expect to file a 510(K) Class 2 filing in the first quarter of 2019. Towards this end, we have several smaller studies planned and underway we expect to include in our submission, which we believe will help support our application, including an animal model in sheep, a comparative study of leachables from a urinary catheter with and without UroShield attached, which is already underway, and a small study of patients with neurogenic bladder dysfunction. Given our past clinical data we are quite confident in our FDA submission and our goal is to receive marketing clearance in the U.S. by the third quarter of 2019, which we believe will be a major milestone for the Company. In the meantime, we are in active discussions with a number of potential partners in the U.S. and abroad, all of which should help drive value for shareholders.
(NAOV) MC $27 Million /Shares Out 6.4 M / Float 1 M / 2 Products approved in US / 1 Potential Blockbuster expected to be approved in Q3 = 1000%+ UPSIDE on this unknown GEM...
NanoVibronix (NAOV)
Market Cap $27 Million
Shares Out 6.4Million
Price $4.10
i24 News Reports on the Effects of the PainShield (APPROVED IN US)
insert-text-here
UroShield: for the prevention of bacterial colonization and biofilm in urinary catheters.Currently CE Marked, an FDA De Novofiling for UroShield is anticipated in 1H 2019. If all goes to plan, the device could make its U.S. introduction later this year. The target market is big(24M indwelling catheters sold in the U.S. each year) and largely underserved (antibiotics are first-line treatment yet often prove to be ineffective)1. Indwelling catheter induced urinary tract infections are commonplaceand, given that they cost the healthcare system billions of dollars each year, hospitals have an economic interest to adopt novel technologies (potentially such as UroShield) that can prevent them.
PainShield: for the treatment of pain, muscle spasms and tendon diseases. The product has U.S. 510(k) clearance, CE Marking and Health Canada regulatory approval.At-home use for trigeminal neuralgia (TN), a neurological condition characterized by extreme pain along the trigeminal nerve in the face, is the main focused market for PainShield. First-line treatment oftrigeminal neuralgia, which causes such severe pain thatit has been called the suicide disease, are anticonvulsants. Surgery and opioids may also be used. While medications can be initially effective, their ability to control the disease usually wanes over time. Estimated U.S. incidence of TN isbetween ~40k and 140k. General soft tissue pain represents a less-defined but relatively enormous market and potent opportunity for PainShield, as does the recent crackdown on opioid overprescribing.
WoundShield: to speed the healing of hard-to-treat wounds.
WoundShield is CE Marked and has Health Canada approval. The chronic wound market is large and encompassesdiabetic foot ulcers (U.S. prevalence is ~5.5M with recurrence rate of 66%), venous leg ulcers (U.S. prevalence is ~600k with one-third recurring four or more times) and pressure ulcers (U.S. incidence of ~2.5M). An estimated $25B or more is spent each year on treating chronic wounds. While there are several modalities of advanced wound therapies available with varying degrees of effectiveness, almost all require operation by a trained clinician and a trip to the hospital. By contrast, WoundShield is designed for at-home use by an individual patient. Another potentially potent, and largely unique, advantage of WoundShield is the ability to use it as an adjunct, or complement, to existing advanced wound care modalities
LungShield: similar in form to UroShield but different in its application, LungShield is designed to reduce the risk of endotracheal infection in a hospital setting. It is currently being evaluated in a human pilot study in patients undergoing mechanical ventilation to determine its effect on development of bacterial colonies on endotracheal tubes
RenooSkin: to facilitate rejuvenationof facial skin.Unlike the NAOVs other products in which the transducer is enclosed in a patch or clip, RenooSkin consists of a head band-like applicator which houses two transducers near each ear. In vitro studies have indicated RenooSkin may be as effective as Retin-A (tretinoin, which generates ~$300M in annual sales)in its ability to rejuvenate skin. Target market is the non-prescription skincare space. Skin care is a very large market, generating ~$8B in annual sales in the U.S. Facial skin care is the fastest growing subcategory within skin care with sales of products such as facemasks, facial moisturizers and facial sprays increasing by as much as 39% annually
We recently met with the FDA and expect to file a 510(K) Class 2 filing in the first quarter of 2019. Towards this end, we have several smaller studies planned and underway we expect to include in our submission, which we believe will help support our application, including an animal model in sheep, a comparative study of leachables from a urinary catheter with and without UroShield attached, which is already underway, and a small study of patients with neurogenic bladder dysfunction. Given our past clinical data we are quite confident in our FDA submission and our goal is to receive marketing clearance in the U.S. by the third quarter of 2019, which we believe will be a major milestone for the Company. In the meantime, we are in active discussions with a number of potential partners in the U.S. and abroad, all of which should help drive value for shareholders.
NNVD = Market Cap $4 Milliion / Shares Out 2 Million / 30 Marketed Products including Cannabis Product / Undiscovered Stock = 20 BAGGER GEM ..
Press Release
https://innovuspharma.com/news/press-releases/
Innovus Pharma’s Subsidiary, Novalere, Inc., Announces Launch of Its First Hemp-Derived Cannabidiol Oil-Based Product, MZS Sleeping Aid™ in the United States
https://finance.yahoo.com/news/innovus-pharma-subsidiary-novalere-inc-110900937.html
NNVD = Market Cap $4 Milliion / Shares Out 2 Million / 30 Marketed Products including Cannabis Product / Undiscovered Stock = 20 BAGGER GEM ..
Press Release
https://innovuspharma.com/news/press-releases/
Innovus Pharma’s Subsidiary, Novalere, Inc., Announces Launch of Its First Hemp-Derived Cannabidiol Oil-Based Product, MZS Sleeping Aid™ in the United States
https://finance.yahoo.com/news/innovus-pharma-subsidiary-novalere-inc-110900937.html
got in at around $2.20 .. Ultra low float gem here could fly like BPTH did from $2 to $73
deep pipeline with 39 Drugs nearing filing for approval / 69 Marketed Drugs in Canada and USA and another 22 Drugs awaiting FDA approval and you get these all for a laughable valuation of $77 million which is a pure gift .
Big Partner deal on the way which means upfront payments
$10 COMINGGGGGGGGGGGGGG
Good News ..and there is 21 more Drugs awaiting FDA approval and 39 Drugs in Pipeline moving closer to FDA filing
Teligent (TLGT), Inc. Announces FDA Approval of Desonide Ointment, 0.05%
https://www.globenewswire.com/news-release/2019/03/14/1753152/0/en/Teligent-Inc-Announces-FDA-Approval-of-Desonide-Ointment-0-05.html
FDA APPROVALLLLLLLLLLLLLLL
10 Million Shares Short oh dear i feel soory for them
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
major breakout is around the corner
TLGT =MCap $70 Million / 69 Drugs on Market in USA & Canada / 22 Drugs awaiting FDA approval / Additional 39 Products in Pipeline / Profitability expected this year / Strong Insider & Institutional Ownership (see below) = Cheapest Pharma play out there with significant upside potential ..Fair value is between $6-8 right NOW .GL
Teligent (TLGT)
Market Cap: $70 Million
Price: $1.31
Shares Out: 53.7 Million
We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).
Institutional Ownership:
Signet Healthcare Partners LLC 9,851,861
venBio Select Advisor LLC 5,299,431
Elk Creek Partners LLC 4,602,755
BlackRock Fund Advisors 3,257,509
Prosight Management LP 3,240,761
Broadfin Capital LLC 3,052,852
AMI Asset Management Corp. 2,714,292
The Vanguard Group, Inc. 2,165,610
Eversept Partners LP 2,112,098
Sanders Morris Harris LLC (Investment Management) 1,545,032
[/img]
[/img]
TLGT =MCap $70 Million / 69 Drugs on Market in USA & Canada / 22 Drugs awaiting FDA approval / Additional 39 Products in Pipeline / Profitability expected this year / Strong Insider & Institutional Ownership (see below) = Cheapest Pharma play out there with significant upside potential ..Fair value is between $6-8 right NOW .GL
Teligent (TLGT)
Market Cap: $70 Million
Price: $1.31
Shares Out: 53.7 Million
We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).
Institutional Ownership:
Signet Healthcare Partners LLC 9,851,861
venBio Select Advisor LLC 5,299,431
Elk Creek Partners LLC 4,602,755
BlackRock Fund Advisors 3,257,509
Prosight Management LP 3,240,761
Broadfin Capital LLC 3,052,852
AMI Asset Management Corp. 2,714,292
The Vanguard Group, Inc. 2,165,610
Eversept Partners LP 2,112,098
Sanders Morris Harris LLC (Investment Management) 1,545,032
over 20% of shares are short and stock is oversold so any good news will let this stock fly like a rocket .
upp she goes
TLGT = Market Cap $70 Million / 69 Drugs on Market in USA & Canada / 22 Drugs awaiting FDA approval / Additional 39 Products in Pipeline / Profitability expected this year / Strong Insider & Institutional Ownership (see below) = Cheapest Pharma play out there with significant upside potential ..Fair value is between $6-8 right NOW .GL
Teligent (TLGT)
Market Cap: $70 Million
Price: $1.31
Shares Out: 53.7 Million
We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).
Institutional Ownership:
Signet Healthcare Partners LLC 9,851,861
venBio Select Advisor LLC 5,299,431
Elk Creek Partners LLC 4,602,755
BlackRock Fund Advisors 3,257,509
Prosight Management LP 3,240,761
Broadfin Capital LLC 3,052,852
AMI Asset Management Corp. 2,714,292
The Vanguard Group, Inc. 2,165,610
Eversept Partners LP 2,112,098
Sanders Morris Harris LLC (Investment Management) 1,545,032
TLGT = Market Cap $70 Million / 69 Drugs on Market in USA & Canada / 22 Drugs awaiting FDA approval / Additional 39 Products in Pipeline / Profitability expected this year / Strong Insider & Institutional Ownership (see below) = Cheapest Pharma play out there with significant upside potential ..Fair value is between $6-8 right NOW .GL
Teligent (TLGT)
Market Cap: $70 Million
Price: $1.31
Shares Out: 53.7 Million
We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).
Institutional Ownership:
Signet Healthcare Partners LLC 9,851,861
venBio Select Advisor LLC 5,299,431
Elk Creek Partners LLC 4,602,755
BlackRock Fund Advisors 3,257,509
Prosight Management LP 3,240,761
Broadfin Capital LLC 3,052,852
AMI Asset Management Corp. 2,714,292
The Vanguard Group, Inc. 2,165,610
Eversept Partners LP 2,112,098
Sanders Morris Harris LLC (Investment Management) 1,545,032
TLGT = Market Cap $70 Million / 69 Drugs on Market in USA & Canada / 22 Drugs awaiting FDA approval / Additional 39 Products in Pipeline / Profitability expected this year / Strong Insider & Institutional Ownership (see below) = Cheapest Pharma play out there with significant upside potential ..Fair value is between $6-8 right NOW .GL
Teligent (TLGT)
Market Cap: $70 Million
Price: $1.31
Shares Out: 53.7 Million
We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).
Institutional Ownership:
Signet Healthcare Partners LLC 9,851,861
venBio Select Advisor LLC 5,299,431
Elk Creek Partners LLC 4,602,755
BlackRock Fund Advisors 3,257,509
Prosight Management LP 3,240,761
Broadfin Capital LLC 3,052,852
AMI Asset Management Corp. 2,714,292
The Vanguard Group, Inc. 2,165,610
Eversept Partners LP 2,112,098
Sanders Morris Harris LLC (Investment Management) 1,545,032
Major breakout to $5 coming
CHEK = MC $17 Million / Cash $18 Million / Shares Out 8.2 Million / ultra Low Float stock with MASSIVE upside potential . $20++ stock trading at ridiculous $2 . RALLYYYYYYYYYYYYYYYYYY
Colorectal Cancer Screening Pill to Be in US Pilot Study
https://www.mddionline.com/colorectal-cancer-screening-pill-be-us-pilot-study
New Presentation
http://ir.check-cap.com/download/CHECK+Corp+Presentation_January+2019.pdf
Check-Cap: This Overlooked Medical Device Company Is Extremely Undervalued
As a result of the much more established market and reimbursement paradigm for capsule endoscopy, in conjunction with C-Scan’s unique ability to circumvent the bowel preparation requirement and detect precancerous polyps, it is conceivable that Check-Cap could scale more than twice as quickly as Given Imaging did since it launched its first product. This implies potential sales for Check-Cap of more than $60M in 2020. Check-Cap believes that the global market opportunity for C-Scan in the US is $5.4B annually (See slide 10 in this presentation), comprised of a global population at age 50 and above of 710 million, an average procedure cost of $600, and a screening frequency of once every 10 years. Hence, $60M of sales contemplates only minimal penetration relative to the aggregate market opportunity. To demonstrate the potential revenue ramp of C-Scan, investors could also study the sales trajectory of Exact Sciences’ (NASDAQ:EXAS) Cologuard. Cologuard generated $26.5M in sales during the first four quarters since the product launched, and within 8 quarters, it exceeded a $100M annualized run-rate.
In my valuation, I was conservative and used only $50M of sales that are only reached in 2022. I used an EV/Sales multiple range of between 5 to 8 (given that the company will still be growing extremely fast). I then conservatively assumed that on top of all warrants being exercised there would be another 100% dilution, so a total of 17M shares. That leads me to a price target in the range of $15.8 and $24.6 at 2022, or 4.5X to 7X current prices. I then assign a 50% chance of success which brings me to a probability weighted price target of $8 to $12.3 or an IRR of 18% to 29%.
However, if you are optimistic and believe the $60M sales in 2020, then $100M of sales is plausible by 2022, and using an 8X multiple, this could potentially be a $800M EV by 2022 or ~$50/share using 15M shares (assuming 75% dilution on top of all warrants being exercised). Obviously, this is pretty much a best case scenario.
RALLYYYYYYYYYYYYYY
CHEK = MC $17 Million / Cash $18 Million / Shares Out 8.2 Million / ultra Low Float stock with MASSIVE upside potential . $20++ stock trading at ridiculous $2 . RALLYYYYYYYYYYYYYYYYYY
Colorectal Cancer Screening Pill to Be in US Pilot Study
https://www.mddionline.com/colorectal-cancer-screening-pill-be-us-pilot-study
New Presentation
http://ir.check-cap.com/download/CHECK+Corp+Presentation_January+2019.pdf
Check-Cap: This Overlooked Medical Device Company Is Extremely Undervalued
As a result of the much more established market and reimbursement paradigm for capsule endoscopy, in conjunction with C-Scan’s unique ability to circumvent the bowel preparation requirement and detect precancerous polyps, it is conceivable that Check-Cap could scale more than twice as quickly as Given Imaging did since it launched its first product. This implies potential sales for Check-Cap of more than $60M in 2020. Check-Cap believes that the global market opportunity for C-Scan in the US is $5.4B annually (See slide 10 in this presentation), comprised of a global population at age 50 and above of 710 million, an average procedure cost of $600, and a screening frequency of once every 10 years. Hence, $60M of sales contemplates only minimal penetration relative to the aggregate market opportunity. To demonstrate the potential revenue ramp of C-Scan, investors could also study the sales trajectory of Exact Sciences’ (NASDAQ:EXAS) Cologuard. Cologuard generated $26.5M in sales during the first four quarters since the product launched, and within 8 quarters, it exceeded a $100M annualized run-rate.
In my valuation, I was conservative and used only $50M of sales that are only reached in 2022. I used an EV/Sales multiple range of between 5 to 8 (given that the company will still be growing extremely fast). I then conservatively assumed that on top of all warrants being exercised there would be another 100% dilution, so a total of 17M shares. That leads me to a price target in the range of $15.8 and $24.6 at 2022, or 4.5X to 7X current prices. I then assign a 50% chance of success which brings me to a probability weighted price target of $8 to $12.3 or an IRR of 18% to 29%.
However, if you are optimistic and believe the $60M sales in 2020, then $100M of sales is plausible by 2022, and using an 8X multiple, this could potentially be a $800M EV by 2022 or ~$50/share using 15M shares (assuming 75% dilution on top of all warrants being exercised). Obviously, this is pretty much a best case scenario.
CHEK = MC $17 Million / Cash $18 Million / Shares Out 8.2 Million / ultra Low Float stock with MASSIVE upside potential . $20++ stock trading at ridiculous $2 . RALLYYYYYYYYYYYYYYYYYY
Colorectal Cancer Screening Pill to Be in US Pilot Study
https://www.mddionline.com/colorectal-cancer-screening-pill-be-us-pilot-study
New Presentation
http://ir.check-cap.com/download/CHECK+Corp+Presentation_January+2019.pdf
Check-Cap: This Overlooked Medical Device Company Is Extremely Undervalued
As a result of the much more established market and reimbursement paradigm for capsule endoscopy, in conjunction with C-Scan’s unique ability to circumvent the bowel preparation requirement and detect precancerous polyps, it is conceivable that Check-Cap could scale more than twice as quickly as Given Imaging did since it launched its first product. This implies potential sales for Check-Cap of more than $60M in 2020. Check-Cap believes that the global market opportunity for C-Scan in the US is $5.4B annually (See slide 10 in this presentation), comprised of a global population at age 50 and above of 710 million, an average procedure cost of $600, and a screening frequency of once every 10 years. Hence, $60M of sales contemplates only minimal penetration relative to the aggregate market opportunity. To demonstrate the potential revenue ramp of C-Scan, investors could also study the sales trajectory of Exact Sciences’ (NASDAQ:EXAS) Cologuard. Cologuard generated $26.5M in sales during the first four quarters since the product launched, and within 8 quarters, it exceeded a $100M annualized run-rate.
In my valuation, I was conservative and used only $50M of sales that are only reached in 2022. I used an EV/Sales multiple range of between 5 to 8 (given that the company will still be growing extremely fast). I then conservatively assumed that on top of all warrants being exercised there would be another 100% dilution, so a total of 17M shares. That leads me to a price target in the range of $15.8 and $24.6 at 2022, or 4.5X to 7X current prices. I then assign a 50% chance of success which brings me to a probability weighted price target of $8 to $12.3 or an IRR of 18% to 29%.
However, if you are optimistic and believe the $60M sales in 2020, then $100M of sales is plausible by 2022, and using an 8X multiple, this could potentially be a $800M EV by 2022 or ~$50/share using 15M shares (assuming 75% dilution on top of all warrants being exercised). Obviously, this is pretty much a best case scenario.
up she goessssssssssssss
Fantastic technology with great potential
High-tech capsule could be alternative to colonoscopy
https://www.israel21c.org/high-tech-capsule-could-be-alternative-to-colonoscopy/